Is Celcuity Inc. (CELC) Halal?

NASDAQ Healthcare United States $5.1B
✓ HALAL
Confidence: 95/100
Celcuity Inc. (CELC) is Halal under 3 of 5 Shariah screening standards, including AAOIFI Standard 21. With a debt ratio of just 1.8% against the AAOIFI threshold of 30%, Celcuity Inc. comfortably passes the key financial ratio tests. The company operates in the Healthcare sector (Biotechnology), which is not a prohibited industry under Islamic finance principles.

Shariah Screening — 5 Standards

Based on financial data from December 2024

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 1.8%
/ 30%
4.4%
/ 30%
0.0%
/ 30%
N/A ✓ HALAL
DJIM 1.8%
/ 33%
4.4%
/ 33%
0.0%
/ 33%
N/A ✓ HALAL
MSCI 40.0%
/ 33%
95.9%
/ 33%
0.7%
/ 33%
N/A ✗ NOT HALAL
S&P 1.8%
/ 33%
4.4%
/ 33%
0.0%
/ 33%
N/A ✓ HALAL
FTSE 40.0%
/ 33%
95.9%
/ 33%
0.7%
/ 50%
N/A ✗ NOT HALAL

Financial Highlights

EPS
$-3.79
P/B Ratio
50.9
EV/EBITDA
-29.1
EV: $5.0B
Revenue
$0
Beta
0.4
Low volatility
Current Ratio
10.5

Profitability

Gross Margin 0.0%
Operating Margin 0.0%
Net Margin 0.0%
Return on Equity (ROE) -163.8%
Return on Assets (ROA) -30.2%

Cash Flow & Balance Sheet

Operating Cash Flow-$83M
Free Cash Flow-$84M
Total Debt$98M
Debt-to-Equity320.1
Current Ratio10.5
Total Assets$245M

Price & Trading

Last Close$114.81
50-Day MA$109.50
200-Day MA$72.05
Avg Volume703K
Beta0.4
52-Week Range
$7.58
$120.31

About Celcuity Inc. (CELC)

CEO
Mr. Brian F. Sullivan
Employees
155
Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
NASDAQ
Market Cap
$5.1B
Currency
USD

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is based in Minneapolis, Minnesota.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is Celcuity Inc. (CELC) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), Celcuity Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is Celcuity Inc.'s debt ratio?

Celcuity Inc.'s debt ratio is 1.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 40.0%.

What are Celcuity Inc.'s key financial metrics?

Celcuity Inc. has a market capitalization of $5.1B. Return on equity stands at -163.8%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.